Advertisement

Hepatology International

, Volume 13, Issue 1, pp 22–24 | Cite as

New generation cancer therapy: right direction for sure with some uncertainty

  • Yoshiyuki UenoEmail author
Invited Commentary

The recent case report by Zacharakis et al. highlights the overwhelming effectiveness of sophisticated cancer immunotherapy along with immune checkpoint inhibitors [1]. The use of this logical approach helped a patient recover completely from advanced breast cancer, as planned by the researchers. This is one of the most famous case reports to date, signifying the landmark triumph of modern anti-cancer immunotherapy. Cancer immunotherapy was theoretically introduced in the early 1980s or even earlier. However, because of their limited clinical effectiveness, the first-generation cancer immunotherapy did not prevail in the clinical settings. Conversely, the advancement in the understanding of the mechanism of T cell activation has further enabled the development of immune checkpoint inhibitory drugs. Notably, anti-CTLA-4 antibody (ipilimumab) and anti-PD-1 antibodies (pembrolizumab and nivolumab) are already approved for the treatment of various solid tumors. For the treatment of...

Notes

Compliance with ethical standards

Conflict of interest

The author does not have any potential conflict of interest regarding this article.

Human and/or animals rights

This article is not applicable to document approval from IRB for research involving human participants and/or animals, and statement regarding obtaining informed consent.

References

  1. 1.
    Zacharakis N, Chinnasamy H, Black M, Xu H, Lu YC, Zheng Z, et al. Immune recognition of somatic mutations leading to complete durable regression in metastatic breast cancer. Nat Med 2018;24(6):724–730CrossRefGoogle Scholar
  2. 2.
    Kudo M. Immuno-oncology in hepatocellular carcinoma: 2017 update. Oncology 2017;93(Suppl 1):147–159CrossRefGoogle Scholar
  3. 3.
    Kudo M. Immune checkpoint inhibition in hepatocellular carcinoma: basics and ongoing clinical trials. Oncology 2017;92(Suppl 1):50–62CrossRefGoogle Scholar
  4. 4.
    Kudo T, Hamamoto Y, Kato K, Ura T, Kojima T, Tsushima T, et al. Nivolumab treatment for oesophageal squamous-cell carcinoma: an open-label, multicentre, phase 2 trial. Lancet Oncol 2017;18(5):631–639CrossRefGoogle Scholar
  5. 5.
    Schmidt N, Flecken T, Thimme R. Tumor-associated antigen specific CD8(+) T cells in hepatocellular carcinoma—a promising target for immunotherapy. Oncoimmunology 2014;3(9):e954919CrossRefGoogle Scholar
  6. 6.
    Omata M, Cheng AL, Kokudo N, Kudo M, Lee JM, Jia J, et al. Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. Hepatol Int 2017;11(4):317–370CrossRefGoogle Scholar
  7. 7.
    Kudo M. New era of the management of liver diseases and liver cancer: state-of-the-art progress in 2017. Dig Dis 2017;35(6):493–497CrossRefGoogle Scholar
  8. 8.
    Kudo M, Finn RS, Qin S, Han KH, Ikeda K, Piscaglia F, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet 2018;391(10126):1163–1173CrossRefGoogle Scholar
  9. 9.
    Bruix J, Qin S, Merle P, Granito A, Huang YH, Bodoky G, et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2017;389(10064):56–66CrossRefGoogle Scholar
  10. 10.
    Kudo M, Hatano E, Ohkawa S, Fujii H, Masumoto A, Furuse J, et al. Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma: Japanese subgroup analysis of the REACH trial. J Gastroenterol 2017;52(4):494–503CrossRefGoogle Scholar
  11. 11.
    Kudo M. Cabozantinib as a second-line agent in advanced hepatocellular carcinoma. Liver Cancer 2018;7(2):123–133CrossRefGoogle Scholar
  12. 12.
    Ikeda M, Mitsunaga S, Ohno I, Hashimoto Y, Takahashi H, Watanabe K, et al. Systemic chemotherapy for advanced hepatocellular carcinoma: past, present, and future. Diseases 2015;3(4):360–381CrossRefGoogle Scholar
  13. 13.
    Hato T, Zhu AX, Duda DG. Rationally combining anti-VEGF therapy with checkpoint inhibitors in hepatocellular carcinoma. Immunotherapy 2016;8(3):299–313CrossRefGoogle Scholar
  14. 14.
    Burr ML, Sparbier CE, Chan YC, Williamson JC, Woods K, Beavis PA, et al. CMTM6 maintains the expression of PD-L1 and regulates anti-tumour immunity. Nature 2017;549(7670):101–105CrossRefGoogle Scholar
  15. 15.
    Chen YG, Satpathy AT, Chang HY. Gene regulation in the immune system by long noncoding RNAs. Nat Immunol 2017;18(9):962–972CrossRefGoogle Scholar
  16. 16.
    Chiba K, Lorbeer FK, Shain AH, McSwiggen DT, Schruf E, Oh A, et al. Mutations in the promoter of the telomerase gene TERT contribute to tumorigenesis by a two-step mechanism. Science 2017;357(6358):1416–1420CrossRefGoogle Scholar
  17. 17.
    Dhar D, Antonucci L, Nakagawa H, Kim JY, Glitzner E, Caruso S, et al. Liver cancer initiation requires p53 inhibition by CD44-enhanced growth factor signaling. Cancer Cell 2018;33(6):1061–77e6CrossRefGoogle Scholar
  18. 18.
    June CH, Sadelain M. Chimeric antigen receptor therapy. N Engl J Med 2018;379(1):64–73CrossRefGoogle Scholar
  19. 19.
    Watanabe K, Luo Y, Da T, Guedan S, Ruella M, Scholler J, et al. Pancreatic cancer therapy with combined mesothelin-redirected chimeric antigen receptor T cells and cytokine-armed oncolytic adenoviruses. JCI Insight 2018; 3(7).  https://doi.org/10.1172/jci.insight.99573
  20. 20.
    Beasley D. The cost of cancer: new drugs show success at a steep price. Reuters. 2017 April 3 2017; Sect. Health News. URL http//www.reuters.com/article/us-usa-healthcare-cancer-costs/the-cost-of-cancer-new-drugs-show-success-at-a-steep-price-idUSKBN1750FU. Accessed 1 July 2018
  21. 21.
    Phallen J, Sausen M, Adleff V, Leal A, Hruban C, White J, et al. Direct detection of early-stage cancers using circulating tumor DNA. Sci Transl Med 2017; 9(403).  https://doi.org/10.1126/scitranslmed.aan2415
  22. 22.
    Desai P, Mencia-Trinchant N, Savenkov O, Simon MS, Cheang G, Lee S, et al. Somatic mutations precede acute myeloid leukemia years before diagnosis. Nat Med 2018;24(7):1015–23CrossRefGoogle Scholar
  23. 23.
    Genovese G, Kahler AK, Handsaker RE, Lindberg J, Rose SA, Bakhoum SF, et al. Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. N Engl J Med 2014;371(26):2477–87CrossRefGoogle Scholar

Copyright information

© Asian Pacific Association for the Study of the Liver 2018

Authors and Affiliations

  1. 1.GastroenterologyYamagata University Faculty of MedicineYamagataJapan

Personalised recommendations